New paradigms in cervical cancer prevention: Opportunities and risks

Guglielmo Ronco, Paolo Giorgi Rossi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Testing for the DNA of high-risk types of papilloma virus (HPV) is more sensitive than cytology in detecting pre-cancerous lesions. One of the main advantages will be the possibility of applying prolonged screening intervals. However adequate screening protocols (age of start and stop, screening intervals, management of HPV positive women) need to be applied in order to avoid over-referral to colposcopy and over-treatment and to maintain sustainable costs. Further follow-up of running trials and research on molecular markers will better define these parameters. The new situation will require organised screening programmes with rigorous protocols and monitoring. This will be even more needed when women vaccinated for HPV 16 and 18 will be screened. Research on how to best screen vaccinated women is a priority. This paper proposes an overview of the plausible impact of new technologies in cervical cancer screening in the near future and in the vaccinated cohorts.

Original languageEnglish
Article number23
JournalBMC Women's Health
Volume8
DOIs
Publication statusPublished - Dec 17 2008

Fingerprint

Papilloma
Uterine Cervical Neoplasms
Viruses
Colposcopy
Risk Management
Early Detection of Cancer
Research
Cell Biology
Referral and Consultation
Technology
Costs and Cost Analysis
DNA
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

New paradigms in cervical cancer prevention : Opportunities and risks. / Ronco, Guglielmo; Rossi, Paolo Giorgi.

In: BMC Women's Health, Vol. 8, 23, 17.12.2008.

Research output: Contribution to journalArticle

@article{919d5507373148a99e3902fa54340e75,
title = "New paradigms in cervical cancer prevention: Opportunities and risks",
abstract = "Testing for the DNA of high-risk types of papilloma virus (HPV) is more sensitive than cytology in detecting pre-cancerous lesions. One of the main advantages will be the possibility of applying prolonged screening intervals. However adequate screening protocols (age of start and stop, screening intervals, management of HPV positive women) need to be applied in order to avoid over-referral to colposcopy and over-treatment and to maintain sustainable costs. Further follow-up of running trials and research on molecular markers will better define these parameters. The new situation will require organised screening programmes with rigorous protocols and monitoring. This will be even more needed when women vaccinated for HPV 16 and 18 will be screened. Research on how to best screen vaccinated women is a priority. This paper proposes an overview of the plausible impact of new technologies in cervical cancer screening in the near future and in the vaccinated cohorts.",
author = "Guglielmo Ronco and Rossi, {Paolo Giorgi}",
year = "2008",
month = "12",
day = "17",
doi = "10.1186/1472-6874-8-23",
language = "English",
volume = "8",
journal = "BMC Women's Health",
issn = "1472-6874",
publisher = "BioMed Central",

}

TY - JOUR

T1 - New paradigms in cervical cancer prevention

T2 - Opportunities and risks

AU - Ronco, Guglielmo

AU - Rossi, Paolo Giorgi

PY - 2008/12/17

Y1 - 2008/12/17

N2 - Testing for the DNA of high-risk types of papilloma virus (HPV) is more sensitive than cytology in detecting pre-cancerous lesions. One of the main advantages will be the possibility of applying prolonged screening intervals. However adequate screening protocols (age of start and stop, screening intervals, management of HPV positive women) need to be applied in order to avoid over-referral to colposcopy and over-treatment and to maintain sustainable costs. Further follow-up of running trials and research on molecular markers will better define these parameters. The new situation will require organised screening programmes with rigorous protocols and monitoring. This will be even more needed when women vaccinated for HPV 16 and 18 will be screened. Research on how to best screen vaccinated women is a priority. This paper proposes an overview of the plausible impact of new technologies in cervical cancer screening in the near future and in the vaccinated cohorts.

AB - Testing for the DNA of high-risk types of papilloma virus (HPV) is more sensitive than cytology in detecting pre-cancerous lesions. One of the main advantages will be the possibility of applying prolonged screening intervals. However adequate screening protocols (age of start and stop, screening intervals, management of HPV positive women) need to be applied in order to avoid over-referral to colposcopy and over-treatment and to maintain sustainable costs. Further follow-up of running trials and research on molecular markers will better define these parameters. The new situation will require organised screening programmes with rigorous protocols and monitoring. This will be even more needed when women vaccinated for HPV 16 and 18 will be screened. Research on how to best screen vaccinated women is a priority. This paper proposes an overview of the plausible impact of new technologies in cervical cancer screening in the near future and in the vaccinated cohorts.

UR - http://www.scopus.com/inward/record.url?scp=61749092389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61749092389&partnerID=8YFLogxK

U2 - 10.1186/1472-6874-8-23

DO - 10.1186/1472-6874-8-23

M3 - Article

C2 - 19091066

AN - SCOPUS:61749092389

VL - 8

JO - BMC Women's Health

JF - BMC Women's Health

SN - 1472-6874

M1 - 23

ER -